Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study
Hiam Chemaitelly, Houssein H. Ayoub, Patrick Tang, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 7, pp. 816-827
Open Access | Times Cited: 70

Showing 1-25 of 70 citing articles:

Differential protection against SARS-CoV-2 reinfection pre- and post-Omicron
Hiam Chemaitelly, Houssein H. Ayoub, Peter Coyle, et al.
Nature (2025)
Open Access | Times Cited: 2
Evolution of SARS-CoV-2 T cell responses as a function of multiple COVID-19 boosters
Ricardo da Silva Antunes, Vicente Fajardo-Rosas, Esther Dawen Yu, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access | Times Cited: 1
Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study
Heba N. Altarawneh, Hiam Chemaitelly, Houssein H. Ayoub, et al.
EBioMedicine (2023) Vol. 95, pp. 104734-104734
Open Access | Times Cited: 32
The immune response to SARS-CoV-2 in people with HIV
Maxine A. Höft, Wendy A. Burgers, Catherine Riou
Cellular and Molecular Immunology (2023) Vol. 21, Iss. 2, pp. 184-196
Open Access | Times Cited: 31
All-cause and COVID-19 mortality in Qatar during the COVID-19 pandemic
Asma Ali Al-Nuaimi, Hiam Chemaitelly, Sandy Semaan, et al.
BMJ Global Health (2023) Vol. 8, Iss. 5, pp. e012291-e012291
Open Access | Times Cited: 23
The imprinting effect of covid-19 vaccines: an expected selection bias in observational studies
Susana Monge, Roberto Pastor‐Barriuso, Miguel A. Hernán
BMJ (2023), pp. e074404-e074404
Open Access | Times Cited: 22
The mRNA-LNP vaccines – the good, the bad and the ugly?
Botond Z. Igyártó, Zhen Qin
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 12
The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses
Konstantin Föhse, Büsra Geckin, Martijn Zoodsma, et al.
Clinical Immunology (2023) Vol. 255, pp. 109762-109762
Open Access | Times Cited: 20
Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections
Hiam Chemaitelly, Houssein H. Ayoub, Sawsan AlMukdad, et al.
Journal of Travel Medicine (2023) Vol. 30, Iss. 5
Open Access | Times Cited: 18
Humoral and cellular immune responses eleven months after the third dose of BNT162b2 an mRNA-based COVID-19 vaccine in people with HIV – a prospective observational cohort study
Line Dam Heftdal, Laura Pérez‐Alós, Rasmus Bo Hasselbalch, et al.
EBioMedicine (2023) Vol. 93, pp. 104661-104661
Open Access | Times Cited: 17
Real-world Effectiveness of mRNA COVID-19 Vaccines Among US Nursing Home Residents Aged ≥65 Years in the Pre-Delta and High Delta Periods
Yun Lu, Arnstein Lindaas, Kathryn Matuska, et al.
Open Forum Infectious Diseases (2024) Vol. 11, Iss. 3
Open Access | Times Cited: 5
Evaluating Hospital Admission Data as Indicators of COVID-19 Severity: A National Assessment in Qatar
Layan Sukik, Hiam Chemaitelly, Houssein H. Ayoub, et al.
Open Forum Infectious Diseases (2025) Vol. 12, Iss. 3
Open Access
All-cause mortality according to COVID-19 vaccination status: An analysis of the UK office for National statistics public data
Marco Alessandria, Giovanni Malatesta, Giovanni Di Palmo, et al.
F1000Research (2025) Vol. 13, pp. 886-886
Open Access
Effectiveness of a fourth SARS‐CoV‐2 vaccine dose in previously infected individuals from Austria
Alena Chalupka, Lukas Richter, Ali Chakeri, et al.
European Journal of Clinical Investigation (2023) Vol. 54, Iss. 3
Open Access | Times Cited: 15
Short- and longer-term all-cause mortality among SARS-CoV-2- infected individuals and the pull-forward phenomenon in Qatar: a national cohort study
Hiam Chemaitelly, Jeremy Samuel Faust, Harlan M. Krumholz, et al.
International Journal of Infectious Diseases (2023) Vol. 136, pp. 81-90
Open Access | Times Cited: 14
Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational study
Suelen H. Qassim, Hiam Chemaitelly, Houssein H. Ayoub, et al.
EClinicalMedicine (2023) Vol. 62, pp. 102102-102102
Open Access | Times Cited: 13
Effectiveness of the fourth dose of COVID-19 vaccines against severe COVID-19 among adults 40 years or older in Brazil: a population-based cohort study
Felippe Lazar Neto, Matt D. T. Hitchings, Avnika B. Amin, et al.
The Lancet Regional Health - Americas (2024) Vol. 34, pp. 100755-100755
Open Access | Times Cited: 4
Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults
Tianyu Sun, Linwei Li, Katherine E. Mues, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 8, pp. 1771-1787
Open Access | Times Cited: 4
Addressing bias in the definition of SARS-CoV-2 reinfection: implications for underestimation
Hiam Chemaitelly, Houssein H. Ayoub, Patrick Tang, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 3
Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study
Hilde S Ørbo, K. H. Bjørlykke, Joseph Sexton, et al.
RMD Open (2024) Vol. 10, Iss. 2, pp. e003545-e003545
Open Access | Times Cited: 3
Protective effect of previous infection and vaccination against reinfection with BA.5 Omicron subvariant: a nationwide population-based study in Japan
Noriko Kitamura, Kanako Otani, Ryo Kinoshita, et al.
The Lancet Regional Health - Western Pacific (2023) Vol. 41, pp. 100911-100911
Open Access | Times Cited: 9
History of primary-series and booster vaccination and protection against Omicron reinfection
Hiam Chemaitelly, Houssein H. Ayoub, Patrick Tang, et al.
Science Advances (2023) Vol. 9, Iss. 40
Open Access | Times Cited: 9
Selective adaptation of SARS-CoV-2 Omicron under booster vaccine pressure: a multicentre observational study
Ralf Duerr, Dacia Dimartino, Christian Marier, et al.
EBioMedicine (2023) Vol. 97, pp. 104843-104843
Open Access | Times Cited: 9
COVID-19 primary series and booster vaccination and potential for immune imprinting
Hiam Chemaitelly, Houssein H. Ayoub, Patrick Tang, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 14
Real-World Effectiveness of a Third Dose of mRNA-1273 versus BNT162b2 on Inpatient and Medically Attended COVID-19 among Immunocompromised Adults in the United States
Tianyu Sun, Linwei Li, Katherine E. Mues, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top